Transformation of Nonfunctioning Pancreatic Neuroendocrine Carcinoma Cells into Insulin Producing Cells after Treatment with Sunitinib
Authors:
Open Access
- 1 January 2013
- journal article
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 28 (2) , 149-152
Abstract
Ohn JH, et al. Endocrinol Metab. 2013 Jun;28(2):149-152. http://dx.doi.org/10.3803/EnM.2013.28.2.149Keywords
This publication has 11 references indexed in Scilit:
- Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: A case reportDiabetes Research and Clinical Practice, 2011
- A Unique Case of a Nonfunctional Metastatic Pancreatic Neuroendocrine Tumor Transforming Into an Insulin-Secreting Tumor With an Unusual Clinical CoursePancreas, 2011
- Potential utility of small tyrosine kinase inhibitors in the treatment of diabetesClinical Science, 2009
- Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes indb/dbMiceDiabetes, 2009
- Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic miceProceedings of the National Academy of Sciences, 2008
- Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinibBritish Journal of Cancer, 2008
- Remission of diabetes while on sunitinib treatment for renal cell carcinomaAnnals of Oncology, 2008
- Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat dietClinical Science, 2007
- Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitroCell Biology International, 2006
- Amelioration of diabetes by imatinib mesylate (Gleevec®): role of ‐cell NF‐KB activation and anti‐apoptotic preconditioningThe FASEB Journal, 2006